Actavis’ Investment Venture To Acquire Stake In Techpool Bio-Pharma
This article was originally published in PharmAsia News
Investor firm Smart Nice, majority-owned by pharmaceutical company Actavis, will accept 20 million shares of Techpool Bio-Pharma from Guangzhou Bopu and buy another 20 million shares at 5 yuan per share. Shanghai Industrial Pharmaceutical Investment and its subsidiary Huarui Investments will decrease their equity in Techpool from 51 percent to 40.8 percent, while Smart Nice will become a strategic investor with 40 percent stake. According to sources, both companies have signed an MOU to collaborate in the areas of medical science, technology, business operation and pharmaceutical-related fields. (Click here for more - Chinese language)
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.